pattern cursor banner


This is a novel lactone ketolide antibiotic designed to target MDR pneumococci, a bacterial pathogen globally contributing to the highest number of mortality despite the wide spread availability of vaccines over the past 15 years. Pneumococci are the leading cause of a range of respiratory tract infections (RTI) encountered in community as well as in hospital settings and cause a significant number of pneumonia and blood stream infections among paediatric and geriatric age groups. The first two lines of traditional RTI therapies based on oral penicillins/cephalosporins and macrolides such as azithromycin and clarithromycin is getting compromised due to the global spread of penicillin and macrolide resistant pneumococci and streptococci. Wockhardt clinical studies have established several clinically attractive attributes of WCK 4873 such as best-in-class oral pharmacokinetic, highest level of lung tissue and alveolar macrophage penetration and good hepatic safety of WCK 4873.

WCK 4873 : Resistant Pathogen coverage:

  • Penicillin and macrolide resistant pneumococci
  • Fluoroquinolone resistant pneumococci
  • Macrolide resistant group B streptococci
  • Penicillin and erythromycin resistant staphylococci
  • Haemophilus influenza & Moraxella cattarahalis
  • Atypical pathogens- Mycoplasma, Legionella, Chlamydia
  • Staphylococci, Pneumococci, Streptococci- paediatric skin to sepsis 3 major Gram positives

WCK 4873 : Indication Potential

  • Community acquired pneumonia
  • Pneumococcal bacteraemia
  • Otitis media
  • Chlamydial urethritis
  • Upper respiratory tract infections


    Publications will be here soon

view all